Allovir, Inc.

AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of AlloVir, Inc. (the “Company”) (NasdaqCM: ALVR) and Kalaris Therapeutics. Pursuant to the terms of the agreement, upon completion of the Merger, pre-Merger AlloVir stockholders are expected to own approximately 25.05% of the combined company. KSF is seeking to determine whether the merger and the process that.

ALLOVIR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AlloVir, Inc. - ALVR

EMCORE

NEW YORK, Nov. 09, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EMKR and ALVR on Behalf of Shareholders

NEW YORK, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating AlloVir , Inc. (NASDAQ: ALVR ), relating to its proposed merger with Kalaris Therapeutics. Under the terms of the agreement, AlloVir will acquire 100% of the outstanding equity interest of Kalaris. Upon completion of the Merger, pre-Merger AlloVir stockholders are expected to own approximately 25.05% of the combined company and pre-Merger Kalaris stockholders are expected to own approximately 74.95% of the combined company.

STOCKHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of AlloVir, Inc. – ALVR

MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating AlloVir (Nasdaq: ALVR) for possible breaches of fiduciary duty and other violations of law in its transaction with Kalaris. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, stockholders of AlloVir will own only approximately 25.05% of the combined company and pre-Merger Kalaris stockh.

Shareholder Alert: Ademi LLP Investigates Whether AlloVir, Inc. Is Obtaining a Fair Price for Its Public Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of AlloVir, Inc. (NASDAQ: ALVR) and Kalaris Therapeutics is fair to AlloVir shareholders. Halper Sadeh encourages AlloVir shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether AlloVir and its board violated the federa.

ALVR Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of AlloVir, Inc. Is Fair to Shareholders

Kalaris is a clinical-stage biopharmaceutical company founded by Samsara BioCapital and focused on development of TH103, a novel, differentiated and potentially transformative therapy for patients with neovascular and exudative retinal diseases

AlloVir and Kalaris Therapeutics Announce Agreement for Transformational Merger to Create Company Focused on Diseases of the Retina

NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of AlloVir, Inc. (NASDAQ: ALVR) breached their fiduciary duties to shareholders.

Kuehn Law Encourages Investors of AlloVir, Inc. to Contact Law Firm

NEW YORK, NY / ACCESSWIRE / March 19, 2024 / If you suffered a loss on your AlloVir, Inc. (NASDAQ:ALVR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/allovir-inc-lawsuit-submission-form?prid=71800&wire=1 or contact Joseph E. Levi, Esq.

Shareholders of AlloVir, Inc. Should Contact Levi & Korsinsky Before March 19, 2024 to Discuss Your Rights - ALVR

NEW YORK , March 19, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against AlloVir, Inc. ("AlloVir" or the "Company") (NASDAQ: ALVR). The class action, filed in the United States District Court for the District of Massachusetts, and docketed under 24-cv-10152, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired AlloVir securities between March 22, 2022 and December 21, 2023, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AlloVir, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALVR

NEW YORK, NY / ACCESSWIRE / March 19, 2024 / If you suffered a loss on your AlloVir, Inc. (NASDAQ:ALVR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/allovir-inc-lawsuit-submission-form?prid=71751&wire=1 or contact Joseph E. Levi, Esq.

AlloVir, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ALVR

NEW YORK, NY / ACCESSWIRE / March 19, 2024 / If you suffered a loss on your AlloVir, Inc. (NASDAQ:ALVR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/allovir-inc-lawsuit-submission-form?prid=71676&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Notifies Shareholders of AlloVir, Inc.(ALVR) of a Class Action Lawsuit and an Upcoming Deadline

LOS ANGELES, CA / ACCESSWIRE / March 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AlloVir, Inc. ("AlloVir" or "the Company") (NASDAQ:ALVR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 22, 2022 and December 21, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before March 19, 2024.

FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm

NEW YORK, NY / ACCESSWIRE / March 18, 2024 / If you suffered a loss on your AlloVir, Inc. (NASDAQ:ALVR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/allovir-inc-lawsuit-submission-form?prid=71543&wire=1 or contact Joseph E. Levi, Esq.

AlloVir, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before March 19, 2024 to Discuss Your Rights - ALVR

NEW YORK, NY / ACCESSWIRE / March 18, 2024 / If you suffered a loss on your AlloVir, Inc. (NASDAQ:ALVR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/allovir-inc-lawsuit-submission-form?prid=71466&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 19, 2024 in AlloVir, Inc. Lawsuit - ALVR

NEW YORK, NY / ACCESSWIRE / March 17, 2024 / If you suffered a loss on your AlloVir, Inc. (NASDAQ:ALVR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/allovir-inc-lawsuit-submission-form?prid=71429&wire=1 or contact Joseph E. Levi, Esq.

Class Action Filed Against AlloVir, Inc. (ALVR) - March 19, 2024 Deadline to Join - Contact Levi & Korsinsky

LOS ANGELES, CA / ACCESSWIRE / March 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AlloVir, Inc. ("AlloVir" or "the Company") (NASDAQ:ALVR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 22, 2022 and December 21, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before March 19, 2024.

FINAL DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in AlloVir, Inc. with Losses of $100,000 to Contact the Firm

NEW YORK, NY / ACCESSWIRE / March 17, 2024 / If you suffered a loss on your AlloVir, Inc. (NASDAQ:ALVR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/allovir-inc-lawsuit-submission-form?prid=71412&wire=1 or contact Joseph E. Levi, Esq.

Shareholders that lost money on AlloVir, Inc.(ALVR) should contact Levi & Korsinsky about pending Class Action - ALVR

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AlloVir, Inc. (NASDAQ: ALVR) between March 22, 2022 and December 21, 2023, both dates inclusive (the “Class Period”), of the important March 19, 2024 lead plaintiff deadline. SO WHAT: If you purchased AlloVir securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO.

ALVR DEADLINE TUESDAY: ROSEN, A LEADING LAW FIRM, Encourages AlloVir, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ALVR

NEW YORK, NY / ACCESSWIRE / March 17, 2024 / If you suffered a loss on your AlloVir, Inc. (NASDAQ:ALVR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/allovir-inc-lawsuit-submission-form?prid=71395&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Reminds AlloVir Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 19, 2024 - ALVR

NEW YORK, NY / ACCESSWIRE / March 17, 2024 / If you suffered a loss on your AlloVir, Inc. (NASDAQ:ALVR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/allovir-inc-lawsuit-submission-form?prid=71373&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Reminds AlloVir, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 19, 2024 - ALVR

NEW YORK, NY / ACCESSWIRE / March 16, 2024 / If you suffered a loss on your AlloVir, Inc. (NASDAQ:ALVR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/allovir-inc-lawsuit-submission-form?prid=71351&wire=1 or contact Joseph E. Levi, Esq.

AlloVir, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before March 19, 2024 to Discuss Your Rights - ALVR

NEW YORK, NY / ACCESSWIRE / March 15, 2024 / If you suffered a loss on your AlloVir, Inc. (NASDAQ:ALVR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/allovir-inc-lawsuit-submission-form?prid=71330&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of AlloVir, Inc.(ALVR) Shareholders

NEW YORK , March 15, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in AlloVir, Inc. ("AlloVir" or the "Company") (NASDAQ: ALVR) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of AlloVir investors who were adversely affected by alleged securities fraud between March 22, 2022 and December 21, 2023.

ALVR LAWSUIT ALERT: Levi & Korsinsky Notifies AlloVir, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

NEW YORK, NY / ACCESSWIRE / March 15, 2024 / If you suffered a loss on your AlloVir, Inc. (NASDAQ:ALVR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/allovir-inc-lawsuit-submission-form?prid=71200&wire=1 or contact Joseph E. Levi, Esq.

March 19, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against - ALVR

NEW YORK, NY / ACCESSWIRE / March 14, 2024 / If you suffered a loss on your AlloVir, Inc. (NASDAQ:ALVR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/allovir-inc-lawsuit-submission-form?prid=71097&wire=1 or contact Joseph E. Levi, Esq.

News for Allovir, Inc. Stock (ALVR)